A study reveals that switching from Humira to Amgevita for IBD maintains disease control and offers significant cost savings.

Biosimilars significantly reduce health care costs in Australia, enhancing access to biologics while driving price competition in the pharmaceutical market. The economic impact of biosimilars on the ...

Number 5: A 10-year prospective follow-up of 244 healthy stem cell donors found no new safety concerns with Sandoz’s filgrastim biosimilar, reinforcing its long-term safety for donor mobilization.